Key Highlights
•
A real-world study in China found that the Alzheimer’s drug lecanemab significantly slowed cognitive decline in patients over six months and was well-tolerated. This provides strong evidence that the treatment is effective and safe outside of controlled clinical trials, offering hope for real-world patient care.
Source →
•
A systematic review found no significant increase in brain swelling or bleeding (known as ARIA) for Alzheimer’s patients on anti-amyloid drugs who were also taking blood thinners. This challenges current safety warnings and suggests these crucial heart medications may be safely combined with new Alzheimer’s treatments for many patients.
Source →
•
Research shows that in people without Alzheimer’s brain plaques (amyloid), the severity of white matter damage in the brain is linked to reduced brain activity and worse memory. This highlights that factors other than amyloid, like blood vessel health, are major drivers of cognitive problems and need to be targeted for treatment.
Source →
•
A study using activity trackers revealed a clear two-way relationship between daytime napping and poor nighttime sleep, where each can worsen the other. This insight helps explain a common cycle of sleep problems and points to managing naps as a potential strategy for improving overall sleep quality.
Source →
•
A new review details how measuring the natural daily rhythm of the stress hormone cortisol, rather than single snapshots, could improve the diagnosis and monitoring of Cushing’s syndrome. This approach could lead to earlier and more accurate detection of this often-missed hormonal disorder.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
